15.11.2021Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology

Press Release
12.11.2021Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC

Press Release
01.11.2021Amphista Therapeutics Appoints CBO, Beverley Carr

Press Release
28.10.2021Aura Biosciences Announces Pricing of Initial Public Offering

Press Release
11.10.2021Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting

Press Release
29.09.2021Aura Biosciences Expands Executive Leadership Team and Board of Directors

Press Release
21.09.2021Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company Focused on Checkpoint Agonist Antibodies

Press Release
21.09.2021Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

Press Release
15.09.2021Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive Officer

Press Release
09.09.2021Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense Mutations

Press Release